Products VAL489 + VAL489 matching placebo
VAL489 + VAL489 matching placebo Phase 3 Completed 📈 Rising Pediatric Hypertension With or Without CKD
Pediatric Hypertension With or Without CKD
Nov 8, 2012 → Jan 24, 2017
About VAL489 + VAL489 matching placebo VAL489 + VAL489 matching placebo is a phase 3 stage product being developed by Novartis for Pediatric Hypertension With or Without CKD. The current trial status is completed. This product is registered under clinical trial identifier NCT01617681. Target conditions include Pediatric Hypertension With or Without CKD.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01617681 Phase 3 Completed Nov 8, 2012 Jan 24, 2017 Pediatric Hypertension With or Without CKD
Competing Products 20 competing products in Pediatric Hypertension With or Without CKD
See all competitors Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3 Denosumab Amgen Phase 3
Other Products from Novartis